AYNE—a novel small-molecule inhibitor of very long-chain acyl-CoA dehydrogenase (VLCAD), which is essential both in FAO and OXPHOS—also reduced ATP production in AML cells, leading to a significant decrease of leukemia burden in preclinical models, sparing normal HSCs [165]. The gene discussed is ACADVL; the disease is acute myeloid leukemia.